Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8500418 | 0.79 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL12936090 | 0.75 | KDM4E (0.33) | ALDH1A1 | |
| SCHEMBL28042959 | 0.74 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1SCN8A | |
| SCHEMBL7951653 | 0.72 | ACHE (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL13313279 | 0.69 | KMT2A (0.49) | ALDH1A1 | |
| SCHEMBL21465037 | 0.68 | GGPS1 (0.39) | — | |
| SCHEMBL28091410 | 0.68 | MAPT (0.35) | SMN1; SMN2ALDH1A1SCN8A | |
| SCHEMBL28061526 | 0.68 | S1PR2 (0.36) | SMN1; SMN2ALDH1A1SCN8A | |
| SCHEMBL13313284 | 0.67 | LMNA (0.53) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL13349221 | 0.67 | KMT2A (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806371-B2 | BY MEANS OF PHASE TRANSFER CATALYSIS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2004-10-19 | — | — | US | disclosed |
| US-20040063957-A1 | Preparation of substituted pyridine N-oxide compounds | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063957-A1 | Preparation of substituted pyridine N-oxide compounds | HRH2, SCO2, CBR1 | SMN1; SMN2 1115/4885ALDH1A1 880/4885SCN8A 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.